Previous study has confirmed that targeting CD19 of CAR-γδ T cells have significantly improved the cytotoxicity of CD19+ tumor cells in vitro and in vivo, indicating that CAR-γδ T cells are expected to be used to tumor immunotherapy [121]. This evidence concerns the gene CD19 and neoplasm.